aTyr Pharma

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its…

SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of…

SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its…

SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines…

SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel…

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel…

 Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways…